BNP Paribas upgraded shares of Qiagen (NYSE:QGEN) from a neutral rating to an outperform rating in a research note published on Friday morning, Briefing.com Automated Import reports.

Other analysts also recently issued reports about the company. Deutsche Bank downgraded Ontex Group from a buy rating to a hold rating in a research report on Wednesday, May 8th. UBS Group reaffirmed a sell rating and issued a $220.00 target price on shares of Tesla in a research report on Friday, March 15th. Zacks Investment Research cut Great Portland Estates from a hold rating to a sell rating in a research note on Tuesday, April 16th. Wolfe Research began coverage on Waters in a research note on Thursday, May 30th. They set an underperform rating for the company. Finally, Goldman Sachs Group cut JSR from a neutral rating to a sell rating in a research note on Friday, June 21st. Five analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Qiagen has a consensus rating of Buy and an average price target of $42.00.

Shares of NYSE QGEN opened at $39.69 on Friday. The firm has a market cap of $8.95 billion, a PE ratio of 29.62, a price-to-earnings-growth ratio of 2.43 and a beta of 0.84. Qiagen has a 12 month low of $32.33 and a 12 month high of $41.55. The stock’s 50 day moving average price is $39.53. The company has a quick ratio of 1.52, a current ratio of 1.69 and a debt-to-equity ratio of 0.54.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Monday, May 6th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.01. Qiagen had a return on equity of 12.22% and a net margin of 12.45%. The company had revenue of $348.70 million for the quarter, compared to analyst estimates of $351.68 million. During the same quarter last year, the firm posted $0.26 EPS. The firm’s revenue for the quarter was up 1.5% on a year-over-year basis. On average, equities analysts forecast that Qiagen will post 1.44 EPS for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of QGEN. O Shaughnessy Asset Management LLC acquired a new position in Qiagen during the first quarter worth $30,000. Captrust Financial Advisors lifted its position in Qiagen by 165.3% during the fourth quarter. Captrust Financial Advisors now owns 1,008 shares of the company’s stock worth $35,000 after buying an additional 628 shares during the period. Cornerstone Advisors Inc. purchased a new position in shares of Qiagen in the 1st quarter worth about $44,000. Truvestments Capital LLC purchased a new position in shares of Qiagen in the 1st quarter worth about $67,000. Finally, Fort L.P. purchased a new position in shares of Qiagen in the 4th quarter worth about $68,000. Institutional investors own 63.20% of the company’s stock.

Qiagen Company Profile

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Featured Article: How to calculate compound interest

Analyst Recommendations for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.